Gilteritinib hemifumarate
Gilteritinib hemifumarate (ASP2215 hemifumarate) is a highly potent, ATP-competitive dual inhibitor targeting FLT3 and AXL kinases, with IC50 values of 0.29 nM and 0.73 nM, respectively. It is a key research compound for studying relapsed or refractory FLT3-mutant acute myeloid leukemia (AML), utilized in both in vitro cellular assays and in vivo xenograft models to investigate therapeutic mechanisms and resistance.
Product Specifications
CAS Number
1254053-84-3
Product Name Alternative
Field of Research
Cardiovascular Research, Pharmacology & Drug Discovery, Signal Transduction
Purity
98.07% (May vary between batches)
Solubility
H2O:1 mg/mL (1.64 mM) ; DMSO:3 mg/mL (4.91 mM)
Smiles
C (=C/C (O) =O) \C (O) =O.N (C=1C (C (N) =O) =NC (CC) =C (NC2CCOCC2) N1) C3=CC (OC) =C (C=C3) N4CCC (CC4) N5CCN (C) CC5
Molecular Formula
C29H44N8O3.1/2C4H4O4
Molecular Weight
610.75
Storage Conditions
-20°C
Notes
For research use only.
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
P4HA2 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV)